Advertisement

“Third Time's a Charm”: Three Times Per Day Dosing of Dofetilide May Be Beneficial in Refractory Atrial Arrhythmias

      Atrial fibrillation and atrial flutter remain the most common arrhythmias in the United States and are projected to affect over 12 million people by the year 2030.
      • Colilla S
      • Crow A
      • Petkun W
      • Singer DE
      • Simon T
      • Liu X.
      Estimates of current and future incidence and prevalence of atrial fibrillation in the U.S. adult population.
      Guidelines have largely favored a rate-control strategy; however, rhythm control in certain patient populations is gaining popularity. Although emerging data suggests benefits of invasive rhythm control strategies, dofetilide, a Vaughan-Williams class 3 antiarrhythmic drug, has gained wide acceptance in the treatment of refractory atrial arrhythmias.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Colilla S
        • Crow A
        • Petkun W
        • Singer DE
        • Simon T
        • Liu X.
        Estimates of current and future incidence and prevalence of atrial fibrillation in the U.S. adult population.
        Am J Cardiol. 2013; 112: 1142-1147
        • Tham TCK
        • Maclennan BA
        • Burke MT
        • Harron DWG.
        Pharmacodynamics and pharmacokinetics of the class III antiarrhythmic agent dofetilide (UK-68,798) in humans.
        J Cardiovasc Pharmacol. 1993; 21: 507-512
        • Allen MJ
        • Nichols DJ
        • Oliver SD.
        The Pharmacokinetics and pharmacodynamics of oral dofetilide after twice daily and three times daily dosing.
        Br J Clin Pharmacol. 2000; 50: 247-253
        • Le Coz F
        • Funck-Brentano C
        • Morell T
        • Ghadanfar MM
        • Jaillon P.
        Pharmacokinetic and pharmacodynamic modeling of the effects of oral and intravenous administrations of dofetilide on ventricular repolarization.
        Clin Pharmacol Ther. 1995; 57: 533-542
        • Lin C
        • Ke X
        • Cvetanovic I
        • Ranade V
        • Somberg J.
        The effect of high extracellular potassium on IKr inhibition by anti-arrhythmic agents.
        Cardiology. 2007; 108: 18-27